# VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management

> **NCT00970892** · — · UNKNOWN · sponsor: **Ankara University** · enrollment: 500 (estimated)

## Conditions studied

- Atrial Fibrillation
- Cardiac Thrombus
- Deep Vein Thrombosis
- Pulmonary Embolism
- Heart Valve Replacement (Mechanical or Biological With AF)
- Cardiomyopathy (Ischemic or Dilated)
- Peripheral Vascular Disease

## Interventions

- **DRUG:** Warfarin dose titration

## Key facts

- **NCT ID:** NCT00970892
- **Lead sponsor:** Ankara University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-07
- **Primary completion:** 2012-07
- **Final completion:** 2012-12
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2009-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00970892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00970892, "VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00970892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*